Latest News

The Big Taboo

New U.K. Study Offers Good News to Sufferers During World Continence Week

22nd June 2020

A new study has been published in the Journal of Medical Economics demonstrating that INNOVO® is a compelling and cost-effective treatment option for Stress Urinary Incontinence in adult females. (Authors: Ash Monga, Mehdi Javanbakht, Ph.D.) You can read details of […]

Read More
Shorla Pharma

Shorla Pharma Closes $8.3m Series A Funding Round

3rd June 2020

Dublin and Clonmel, Ireland. June 4, 2020.   Shorla Pharma Limited (‘Shorla’), an Irish specialty pharmaceutical company has today announced the completion of a Series A investment of $8.3m.  The financing was led by Seroba Life Sciences (‘Seroba’), a European Venture […]

Read More

Quanta provides compact dialysis systems to NHS to support increased need caused by COVID-19 pandemic

1st June 2020

Alcester, Warwickshire, UK, 01 June 2020:  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology innovation company, today announced that it has been proudly supporting the ongoing National Health Service (NHS) COVID-19 response for emergency […]

Read More

Fusion Pharmaceuticals Appoints New Chief Medical Officer

23rd March 2020

23 March 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of James J. O’Leary, M.D., as chief medical […]

Read More
Endotronix 025 Lo (002)

Endotronix Announces Enrollment of the First Patients in the PROACTIVE-HF Pivotal Trial

18th February 2020

LISLE, IL – February 18, 2020 – Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF […]

Read More
Cancer Killers

Fusion Announces the Appointment of Pablo J. Cagnoni, M.D. to its Board of Directors

6th February 2020

Boston, MA & Hamilton, February 6, 2020.   Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted alpha therapeutics, has announced the appointment of Pablo J. Cagnoni, M.D., to the board of directors. Dr. Cagnoni’s appointment as […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top